Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Authors :: Kaufman, Jonathan L. Usmani, Saad Z. San-Miguel, Jesus and Bahlis, Nizar White, Darrell J. Benboubker, Lotfi Cook, Gordon Leiba, Merav Ho, P. Joy Kim, Kihyun Takezako, Naoki Moreau, Philippe Krevvata, Maria Pei, Huiling and Ukropec, Jon Renaud, Thomas Trivedi, Sonali Kobos, Rachel and Dimopoulos, Meletios A.
Publication Year :: 2019

Tools